Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome

Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome

Objective: Evaluate the efficacy and safety of elagolix, a GnRH antagonist, to treat polycystic ovarian syndrome (PCOS). Design: A phase 2, multicenter, double-blind, randomized, placebo-controlled trial. Setting: Outpatient and academic medical centers. Patient(s): One hundred fourteen women with P...

Full description

Bibliographic Details
Main Authors: Michael C. Snabes, M.D., Ph.D., Juki Ng, Pharm.D., Ph.D., Hong Li, Ph.D., Izna Ali, Pharm.D., Ph.D., Mohamad Shebley, Ph.D., William D. Schlaff, M.D
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:F&S Reports
Subjects:
Polycystic ovarian syndrome
elagolix
menstrual cycle
ovulation
GnRH antagonist
Online Access:http://www.sciencedirect.com/science/article/pii/S2666334123000156

Internet

http://www.sciencedirect.com/science/article/pii/S2666334123000156

Similar Items